EVFM
NASDAQEvofem Biosciences Inc.
Evofem Biosciences Inc. (EVFM) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for EVFM, including 1 SEC filing. The most recent was published Oct 15, 2026.
News · 26 weeks70%
2026-05-102026-11-01
Mix290d
- SEC Filings2(100%)
Latest news
25 items- SECSEC Form 8-K filed by Evofem Biosciences Inc.8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- PRHUB Cyber Security Expands Into Women’s Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet TurnaroundTEL AVIV, Israel, July 01, 2026 (GLOBE NEWSWIRE) -- HUB Cyber Security Ltd. (NASDAQ:HUBC) ("HUB" or the "Company"), today announced that it has acquired certain senior subordinated convertible notes and purchase rights of Evofem Biosciences, Inc. (OTC:EVFM) ("Evofem"), funded entirely with HUB equity at no cash cost to the Company. The transaction is the latest step in a broader transformation plan to strengthen HUB’s financial position, streamline operations, enhance governance and build long-term shareholder value. The notes and purchase rights were acquired directly from certain Evofem noteholders in exchange solely for HUB equity securities, consisting of ordinary shares and/or pre-fu
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECSEC Form 10-Q filed by Evofem Biosciences Inc.10-Q - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECSEC Form 8-K filed by Evofem Biosciences Inc.8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECSEC Form 10-K filed by Evofem Biosciences Inc.10-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- PRFavorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE— PHEXX® Poised to Become First and Only Hormone-Free Contraceptive Vaginal Gel Approved in UAE — — 2026 Launch Planned for Hormone-Free Contraceptive in UAE — SAN DIEGO, Nov. 21, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) announced today that the Emirates Drug Establishment (EDE) has issued favorable pricing certificates for PHEXX® (lactic acid, citric acid, potassium bitartrate), which is a preliminary administrative step toward regulatory approval in the United Arab Emirates (UAE). EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovat
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- PREvofem Reports Financial Results for Third Quarter of 2025, Provides Business Update-- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter -- -- Delivered $1.0 Million of Operating Income in Q3 2025 -- SAN DIEGO, Nov. 13, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and nine-month periods ended September 30, 2025 and provided a business update. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Sales rebounded in the thi
- SECSEC Form 10-Q filed by Evofem Biosciences Inc.10-Q - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECSEC Form DEF 14A filed by Evofem Biosciences Inc.DEF 14A - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECSEC Form PRE 14A filed by Evofem Biosciences Inc.PRE 14A - Evofem Biosciences, Inc. (0001618835) (Filer)
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- PREvofem Announces Voting Results from Special Meeting of Stockholders-- Evofem Shareholders Did Not Approve the Merger with Aditxt -- -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales -- SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) ("Evofem" or the "Company"), today announced that at a Special Meeting of Stockholders held this morning, its stockholders did not approve the proposal to adopt the Amended and Restated Merger Agreement dated July 12, 2024, as subsequently amended (the "Merger Agreement"), between the Company, Aditxt, Inc. (NASDAQ:ADTX), and Adifem, Inc., a wholly owned subsidiary of Aditxt, under which Aditxt intended to acquire Evofem. As a result, Evofem has exercised
- SECEvofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
- PREvofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates— First ex-U.S. Regulatory Filing for SOLSOEC® — — Pharma 1 Targets 1H 2026 Launch in UAE for SOLOSEC® to Treat Bacterial Vaginosis and Trichomoniasis, leveraging its commercial infrastructure and expertise in women's health — SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem, or the Company) (OTCID: EVFM) announced today that its licensee for the Middle East and North Africa (MENA), private Emirati health care company Pharma 1, has filed an application with the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) seeking approval to commercialize SOLOSEC® (secnidazole) 2 g oral granules, Evofem's FDA-approved single-dose oral t
- PREvofem Biosciences Honors World Contraception DaySAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- On World Contraception Day, Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCID: EVFM) honors the millions of people worldwide who rely on contraception not only to prevent pregnancy, but to take control of their health, their futures, and their freedom. Access to contraception remains uneven across countries and communities; the need for more education, innovation, and de-stigmatization has never been greater. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">
EVFM FAQ
8 questionsWhat does Evofem Biosciences Inc. do?
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about...What is the latest news on EVFM?
In the last 30 days Quantisnow tracked 1 wire item for EVFM: 1 SEC filing. The most recent was published on October 15, 2026.Where does EVFM stock trade?
Evofem Biosciences Inc. (EVFM) is listed on NASDAQ.What sector and industry is EVFM in?
Evofem Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Evofem Biosciences Inc. go public?
Evofem Biosciences Inc. (EVFM) completed its IPO in 2014.What are analysts saying about EVFM?
Across the last 5 analyst actions on Evofem Biosciences Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Morgan Stanley: Underweight with a $0.53 price target on 2022-03-04. Recent price targets range from $0.53 to $2.50.What companies are similar to EVFM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EVFM side-by-side with any of them on Quantisnow.How can I track EVFM on Quantisnow?
Quantisnow aggregates Evofem Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EVFM to receive live email and push alerts on every new disclosure.